Acute Respiratory Distress Syndrome Treatment Market By Treatment Modality (Mechanical Ventilation, Oxygen Therapy and High-Flow Nasal Oxygen, Prone-Positioning and Supportive Care, Fluid Management, VV-ECMO, Pharmacotherapy, Investigational Biologics and Cell-Derived Therapies); By Drug Class (Corticosteroids, Anti-Infective Agents, Sedatives and Analgesics, Neuromuscular Blocking Agents, Loop Diuretics, Vasopressors, Anticoagulants, Other Supportive Medicines); By ARDS Severity (Mild ARDS, Moderate ARDS, Severe ARDS); By Etiology (Pneumonia-Associated ARDS, Sepsis-Associated ARDS, Aspiration-Associated ARDS, Trauma-Associated ARDS, Transfusion-Associated ARDS, Pancreatitis-Associated ARDS, Burns and Inhalational Injury-Associated ARDS, Other Causes); By End User (Hospitals and Intensive Care Units, Tertiary and Academic Medical Centers, Specialty Pulmonary and Critical-Care Centers, ECMO and Advanced Respiratory-Support Centers); By Geography, Segment Revenue Estimation, Forecast, 2026–2032

Acute Respiratory Distress Syndrome (ARDS) Treatment Market

Critical-Care Infrastructure Defines the Market

The Global Acute Respiratory Distress Syndrome Treatment Market was valued at USD 3.32 billion in 2025 and is projected to reach USD 5.13 billion by 2032, expanding at a CAGR of 6.4% during 2026–2032, according to Strategic Market Research.

The acute respiratory distress syndrome treatment market remains centered on intensive-care delivery rather than a single disease-modifying medicine. ARDS develops after severe pneumonia, sepsis, aspiration, trauma, pancreatitis, transfusion, burns, or inhalational injury. These triggers damage the alveolar–capillary barrier, producing inflammatory pulmonary edema and severe oxygenation failure. Treatment revenue is therefore spread across ventilators, oxygen-delivery systems, monitoring equipment, infusion products, respiratory consumables, prone-positioning systems, extracorporeal membrane oxygenation equipment, established hospital medicines, and investigational biologics.

More than 3 million people are estimated to develop ARDS worldwide each year. A widely cited historical U.S. population study estimated approximately 190,000 annual cases, 74,500 deaths, and 3.6 million hospital days. These U.S. figures are useful burden indicators but should not be treated as current forecasts because ARDS identification, coding, respiratory-support practices, and underlying disease patterns have changed.

The newer global ARDS definition may increase the identifiable treatment population. It includes patients receiving high-flow nasal oxygen at 30 litres per minute or more, permits the use of the SpO2/FiO2 ratio, accepts lung ultrasound for identifying bilateral opacities, and provides modified criteria for resource-limited settings. Earlier recognition expands the addressable population for high-flow oxygen systems, pulse oximeters, lung ultrasound, noninvasive respiratory support, and trials enrolling patients before intubation.

 

Patient Numbers and Deaths Increase With ARDS Severity

The LUNG SAFE study provides one of the strongest multinational assessments of ARDS patient volume and mortality. It screened 29,144 admissions across 459 ICUs in 50 countries and identified 3,022 ARDS patients. ARDS represented 10.4% of ICU admissions and 23.4% of patients receiving mechanical ventilation. Among 2,377 patients who developed ARDS within the first 48 hours and received invasive ventilation, moderate ARDS was the largest severity group.

ARDS severity distribution in the cohort included 714 patients with mild ARDS, representing 30.0% of the total population, with 249 hospital deaths and a hospital mortality rate of 34.9%. Moderate ARDS accounted for the largest group with 1,106 patients, or 46.6% of the cohort, and this subgroup experienced 446 hospital deaths with a mortality rate of 40.3%. Severe ARDS included 557 patients, representing 23.4% of the cohort, and was associated with 257 hospital deaths and the highest mortality rate of 46.1%. Overall, the study population comprised 2,377 patients, with 952 hospital deaths and an overall hospital mortality rate of 40.0%.

Mortality increased with worsening oxygenation, while ventilator-free days declined. Severe cases consequently generate disproportionate demand for prolonged ventilation, prone positioning, continuous neuromuscular blockade, advanced monitoring, ECMO assessment, and longer critical-care support. Practice gaps also remain material: plateau pressure was measured in only 40.1% of invasively ventilated patients, and prone positioning was used in 16.3% of severe cases in LUNG SAFE.

 

Pneumonia and Sepsis Create the Largest High-Risk Patient Groups

ARDS patients can have more than one initiating condition, so cause-specific counts cannot be added to produce a global total. In LUNG SAFE, 1,794 of the 3,022 patients had pneumonia, 484 had extrapulmonary sepsis, 430 had aspiration, 226 had noncardiogenic shock, 127 had trauma, and 118 had transfusion-related risk. Pneumonia alone was recorded in 59.4% of the cohort, making infection management a major determinant of antibiotic use, microbiological testing, source control, ventilation duration, and mortality.

A multicenter analysis of 2,138 patients from the China Critical Care Sepsis Trial further separated ARDS by sepsis status and whether the initial injury originated within or outside the lungs.

ARDS can be categorized into several clinically distinct groups based on the presence or absence of sepsis and whether the primary injury originates in the lungs or outside the lungs. In sepsis-induced pulmonary ARDS, there are 647 patients, with 297 ICU deaths corresponding to a mortality rate of 45.9%, and 339 hospital deaths corresponding to 52.4% mortality. In sepsis-induced extrapulmonary ARDS, there are 396 patients, with 91 ICU deaths (23.0%) and 118 hospital deaths (29.8%). Non-sepsis pulmonary ARDS includes 536 patients, with 126 ICU deaths (23.5%) and 181 hospital deaths (33.8%). Non-sepsis extrapulmonary ARDS comprises 559 patients, with 163 ICU deaths (29.2%) and 199 hospital deaths (35.6%).

Sepsis-induced pulmonary ARDS had the highest mortality and only five ventilator-free days within 28 days, compared with nine days for sepsis-induced extrapulmonary ARDS, 13 days for non-sepsis pulmonary ARDS, and 12 days for non-sepsis extrapulmonary ARDS. These findings come from an 18-ICU Chinese cohort and should not be presented as global disease shares, but they show why pneumonia combined with sepsis creates particularly intensive treatment requirements.

Etiology also affects prognosis in clinical-trial populations. An analysis of 2,914 ARDS Network participants reported 28-day mortality of 32.29% for sepsis-associated ARDS, 24.91% for pneumonia, 23.06% for aspiration, 8.81% for trauma, and 24.14% for other causes. These are cohort-specific rates rather than universal mortality estimates. The lower mortality observed in trauma-associated ARDS also indicates that one treatment effect cannot be assumed across infection, aspiration, trauma, and systemic inflammatory disease.

 

Ventilation, Proning, Fluid Control, and ECMO Remain the Revenue Base

Mechanical ventilation is the main treatment platform for moderate-to-severe ARDS. Lung-protective protocols generally use tidal volumes of 4–8 mL per kilogram of predicted body weight and maintain plateau pressure below 30 cm H2O. Commercial demand favors ventilators that provide accurate pressure and volume control, PEEP adjustment, respiratory-mechanics measurements, waveform analysis, alarm management, and integration with patient-monitoring systems.

Updated American Thoracic Society guidance conditionally recommends corticosteroids for ARDS, neuromuscular blockade in early severe disease, higher PEEP without prolonged recruitment manoeuvres in moderate-to-severe disease, and VV-ECMO for carefully selected patients after ventilation and prone positioning have been optimized. Low-tidal-volume ventilation and prolonged prone positioning in severe ARDS remain strongly supported.

Conservative fluid management reduces hydrostatic pressure and pulmonary edema after shock has been stabilized. In the 1,000-patient FACTT study, conservative and liberal strategies produced no significant difference in 60-day mortality, but conservative management increased ventilator-free days from 12.1 to 14.6 and ICU-free days from 11.2 to 13.4 during the first 28 days. The commercial value of fluid management therefore lies in potentially reducing ventilation and ICU duration rather than directly lowering mortality.

VV-ECMO addresses a much smaller but higher-cost segment. Each case requires pumps, oxygenators, cannulae, tubing, anticoagulation, laboratory testing, specialist personnel, and prolonged monitoring. Its use remains concentrated in experienced referral centers because bleeding, thrombosis, infection, cannulation complications, and staffing requirements limit wider deployment.

 

Drug Types Used in Current ARDS Care

No pharmacotherapy is broadly approved to reverse all-cause ARDS. Most medicines either manage the initiating condition or enable safe delivery of respiratory and organ support.

Corticosteroids such as dexamethasone, methylprednisolone, and hydrocortisone act by binding intracellular glucocorticoid receptors and suppressing inflammatory gene transcription. In ARDS, they are used selectively to reduce inflammatory lung injury or to manage underlying conditions such as severe pneumonia or septic shock. Although clinical guidelines provide a conditional recommendation for their use, there is significant variability in the choice of agent, dosing strategy, timing of initiation, duration of therapy, and the underlying cause of ARDS, which prevents the establishment of a single standardized treatment regimen.

Antibiotics, antivirals, and antifungal agents function by inhibiting or eliminating the infectious pathogens responsible for pneumonia, sepsis, or opportunistic infections. These therapies address the initiating disease process rather than ARDS itself. Their use is guided by microbiological findings, local antimicrobial resistance patterns, the source of infection, and structured de-escalation protocols. The widespread use of these agents also supports the broader infrastructure of diagnostic testing and antimicrobial stewardship programs in critical care settings.

Sedatives and analgesics, including agents such as propofol, dexmedetomidine, midazolam, and opioids, act through GABAergic, alpha-2 adrenergic, or opioid receptor pathways to ensure patient comfort and improve tolerance of mechanical ventilation and prone positioning. These drugs are used extensively in patients requiring prolonged ventilation; however, there is an increasing clinical emphasis on minimizing deep sedation and reducing delays in mobilization to improve long-term outcomes.

Neuromuscular blocking agents such as cisatracurium work by blocking nicotinic acetylcholine receptors at the neuromuscular junction, thereby eliminating spontaneous muscle activity and reducing severe patient–ventilator asynchrony. Their use is generally reserved for selected cases of early severe ARDS because routine paralysis necessitates deep sedation and increases the need for intensive monitoring.

Loop diuretics, particularly furosemide, inhibit the sodium-potassium-chloride transporter in the loop of Henle, promoting fluid excretion. In ARDS management, they are primarily used to support conservative fluid strategies after hemodynamic stabilization, although they do not directly repair alveolar damage.

Vasopressors such as norepinephrine and vasopressin increase vascular tone to maintain adequate organ perfusion in patients experiencing septic or distributive shock. Their use is most prominent in sepsis-associated ARDS and tends to increase in patients with multiorgan failure.

Anticoagulants, including unfractionated heparin and low-molecular-weight heparins, enhance antithrombin activity to reduce the risk of clot formation. In ARDS care, they are commonly used for venous thromboembolism prophylaxis and for managing extracorporeal membrane oxygenation circuits, with dosing carefully adjusted due to the elevated risk of bleeding in critically ill patients.

The established-drug segment therefore produces substantial treatment volume but limited product differentiation because many products are generic. Greater commercial value is likely to come from a therapy that reduces mortality, ventilation duration, ECMO use, or ICU length of stay in a clearly identifiable patient group.

 

Pipeline Moves Toward Host-Directed and Phenotype-Specific Therapy

ALT-100 – eNAMPT neutralization: Aqualung Therapeutics developed ALT-100 as an intravenous monoclonal antibody against extracellular nicotinamide phosphoribosyltransferase. Blocking eNAMPT is intended to reduce TLR4 and NF-κB signalling, innate immune activation, and vascular leakage. The Phase 2a PUERTA study enrolled only 15 moderate-to-severe ARDS patients before financial and recruitment constraints ended the program early. Ten received ALT-100 and five received placebo. Safety outcomes were comparable, while ventilator-free-day and biomarker findings remained exploratory and underpowered. The small sample does not establish efficacy but clinically validated the target for future development.

Reparixin – CXCR1/CXCR2 inhibition: Reparixin is an allosteric inhibitor of CXCR1 and CXCR2 that interrupts IL-8-mediated neutrophil recruitment and activation. The completed Phase 2 RESPIRATIO study, NCT05496868, targeted 66 adults with moderate-to-severe ARDS and assessed lung injury, systemic inflammation, ventilator liberation, and hyperinflammatory biomarkers. Definitive efficacy results had not been publicly posted in the retrieved registry record, limiting assessment of its competitive position.

Vilobelimab – complement C5a blockade: Vilobelimab binds complement component C5a and limits C5a-driven inflammation while preserving downstream C5b-mediated membrane attack complex formation. Under the brand Gohibic, it received EU authorization under exceptional circumstances in January 2025 for a narrow population of adults with SARS-CoV-2-induced ARDS receiving systemic corticosteroids and invasive ventilation, with or without ECMO. It is not a broad approval for all-cause ARDS. The recruiting Phase 2 JUST BREATHE cohort, NCT06701682, is evaluating vilobelimab in approximately 200 hospitalized ARDS patients, with 28-day mortality as the primary endpoint.

Paridiprubart – TLR4 blockade: Paridiprubart is an intravenous monoclonal antibody designed to prevent TLR4 dimerization and downstream inflammatory signalling. In a company-reported, prematurely discontinued Phase 3 COVID-19 ARDS study involving 104 invasively ventilated patients, adjusted 28-day mortality was reported at 39% with paridiprubart and 52% with placebo; 60-day mortality was 46% and 59%, respectively. A later company analysis covering 278 randomized patients reported adjusted 28-day mortality of 24% versus 33%. These results were disclosed through company SEC filings and require independent peer-reviewed confirmation. The molecule is also being tested in the approximately 200-patient Phase 2 JUST BREATHE all-cause ARDS cohort, NCT06701669.

Bevacizumab – VEGF inhibition: This established oncology antibody binds vascular endothelial growth factor and prevents VEGF-receptor activation. Its ARDS rationale is to reduce abnormal endothelial permeability and pulmonary vascular leakage. The recruiting Phase 2 JUST BREATHE cohort, NCT06701656, expects approximately 200 patients. Resource use, intubation days, ICU stay, oxygenation, and survival are being measured alongside safety. Existing risks involving bleeding, thrombosis, hypertension, impaired wound healing, and gastrointestinal perforation could restrict eligibility and adoption in critically ill patients.

ExoFlo – mesenchymal stromal cell-derived extracellular vesicles: ExoFlo contains bone-marrow-derived extracellular vesicles carrying multiple proteins, lipids, RNA molecules, and immunoregulatory signals. The proposed effect is broader modulation of inflammation and tissue repair rather than inhibition of one receptor. The Phase 3 EXTINGUISH ARDS study, NCT05354141, is evaluating intravenous ExoFlo against placebo in moderate-to-severe ARDS, with 60-day all-cause mortality as the main endpoint. Commercialization would also depend on donor control, manufacturing consistency, potency testing, storage, and regulatory comparability between production batches.

 

Market Outlook

ARDS treatment will remain dependent on ventilators, oxygen delivery, respiratory consumables, prone-positioning support, fluid management, infection treatment, monitoring, and ECMO. Moderate ARDS represents the largest severity group, while severe and sepsis-induced pulmonary ARDS generate the greatest mortality and resource intensity.

The pharmaceutical opportunity is moving toward host-directed agents that can work across several infectious or inflammatory triggers. However, biological heterogeneity remains the main development barrier. A therapy may fail in an undifferentiated ARDS population even when it benefits patients with complement activation, excessive TLR4 signalling, neutrophil-driven inflammation, vascular leakage, or a hyperinflammatory phenotype.

Commercial adoption will depend less on short-term oxygenation changes and more on mortality, ventilator-free days, avoidance of ECMO, ICU length of stay, and functional recovery. Therapies linked to rapid biomarkers or practical clinical phenotypes will have a stronger positioning advantage because hospitals need to identify eligible patients within hours of ARDS onset.

 

7.1. Report Coverage Table

Report Attribute	Details
Forecast Period	2026–2032
Market Size Value in 2025	USD 3.32 Billion
Revenue Forecast in 2032	USD 5.13 Billion
Overall Growth Rate	CAGR of 6.4% during 2026–2032
Base Year for Estimation	2025
Historical Data	2019–2024
Unit	USD Million, CAGR during 2026–2032
Segmentation	By Treatment Modality, By Drug Class, By ARDS Severity, By Etiology, By End User, By Geography
By Treatment Modality	Mechanical Ventilation, Oxygen Therapy and High-Flow Nasal Oxygen, Prone-Positioning and Supportive Care, Fluid Management, VV-ECMO, Pharmacotherapy, Investigational Biologics and Cell-Derived Therapies
By Drug Class	Corticosteroids, Anti-Infective Agents, Sedatives and Analgesics, Neuromuscular Blocking Agents, Loop Diuretics, Vasopressors, Anticoagulants, Other Supportive Medicines
By ARDS Severity	Mild ARDS, Moderate ARDS, Severe ARDS
By Etiology	Pneumonia-Associated ARDS, Sepsis-Associated ARDS, Aspiration-Associated ARDS, Trauma-Associated ARDS, Transfusion-Associated ARDS, Pancreatitis-Associated ARDS, Burns and Inhalational Injury-Associated ARDS, Other Causes
By End User	Hospitals and Intensive Care Units, Tertiary and Academic Medical Centers, Specialty Pulmonary and Critical-Care Centers, ECMO and Advanced Respiratory-Support Centers
By Region	North America, Europe, Asia-Pacific, Latin America, Middle East and Africa
Country Scope	U.S., Canada, UK, Germany, France, Italy, Spain, China, Japan, South Korea, India, Australia, Brazil, Mexico, Saudi Arabia, UAE, South Africa
Market Drivers	Rising incidence of severe pneumonia and sepsis, expansion of ICU and mechanical-ventilation capacity, broader adoption of high-flow oxygen and lung-protective ventilation, increasing use of prone positioning and advanced monitoring, growth of ECMO referral networks, and development of phenotype-specific biologic therapies
Customization Option	Available upon request